Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1017/S1461145714000790 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Modern pharmacotherapy guidance for treating alcohol use disorders.
Expert Opin Pharmacother
December 2024
Forel Clinic, Addiction Treatment Center, Switzerland.
Introduction: Alcohol use disorder (AUD) is prevalent and recognized as a chronic, relapsing disorder. Even though effective treatment options are available, AUD is strongly undertreated. As adjuvant treatment strategies accompanying psychosocial treatments, pharmacological strategies can increase the efficacy of AUD treatment options.
View Article and Find Full Text PDFComparative effects of topiramate and naltrexone on neural activity during anticipatory anxiety in individuals with alcohol use disorder.
Alcohol Alcohol
November 2024
Specialty of Addiction Medicine, Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, NSW 2050, Australia.
Article Synopsis
- - Topiramate has shown effectiveness in reducing alcohol use and possibly lowering anxiety severity in patients with alcohol use disorder (AUD), compared to naltrexone, another medication used for AUD.
- - In a study with 42 treatment-seeking AUD patients, participants were given either topiramate or naltrexone for 12 weeks, and their neural responses to an anxiety-inducing task were measured using fMRI after 6 weeks of treatment.
- - The study found no major differences in brain activation between the two treatment groups, but it noted that changes in anxiety levels were linked to the brain's response to threat cues, providing insights into how these medications may work.
The Safety of Alcohol Pharmacotherapies in Pregnancy: A Scoping Review of Human and Animal Research.
CNS Drugs
January 2025
School of Population and Global Health, University of Western Australia, Nedlands, WA, 6009, Australia.
Article Synopsis
- - The study reviews the safety concerns of various alcohol pharmacotherapies during pregnancy, as current options for pregnant individuals with alcohol use disorders (AUD) are limited due to unknown teratogenic risks.
- - A total of 105 studies were analyzed, focusing on medications like naltrexone, acamprosate, disulfiram, and topiramate, with findings suggesting that naltrexone might be safer than other options for opioid use disorders, despite being less studied for AUD specifically.
- - The review highlights significant safety concerns, noting disulfiram and topiramate's links to congenital anomalies, while acamprosate showed potential neuroprotective benefits without clear adverse effects, creating a complex picture of risks and benefits
Topiramate-induced acute eosinophilic pneumonia.
BMJ Case Rep
September 2024
AFMC Campus, Pune, Maharashtra, India.
Article Synopsis
- * Investigations showed elevated eosinophil counts and serum IgE levels, leading to a diagnosis of eosinophilic pneumonia after other causes were ruled out.
- * The condition was linked to the medication topiramate, which he started for alcohol withdrawal seizures, and stopping the drug resolved all symptoms and imaging abnormalities.
Topiramate Versus Naltrexone for Alcohol Use Disorder: A Genotype-Stratified Double-Blind Randomized Controlled Trial.
Am J Psychiatry
May 2024
Specialty of Addiction Medicine, Sydney Medical School (Morley, Adams, Montebello, Tremonti, Dali, Logge, Haber), School of Health Sciences (Baillie), and Matilda Centre for Mental Health and Substance Use (Teesson), Faculty of Medicine and Health, University of Sydney, Sydney, Australia; Edith Collins Centre for Translational Research in Alcohol, Drugs, and Toxicology (Morley, Jamshidi, Logge, Haber) and Department of Medical Genomics (Luquin, Trent), Royal Prince Alfred Hospital, Camperdown, Australia; Center for Studies of Addiction, Perelman School of Medicine, University of Pennsylvania, and Mental Illness Research, Education, and Clinical Center, Crescenz VA Medical Center, Philadelphia (Kranzler); Northern Sydney Local Health District Drug and Alcohol Services, St Leonards, Australia (Montebello); St Vincent's Hospital Sydney, Sydney, Australia (Tremonti).
Objective: There have been no well-controlled and well-powered comparative trials of topiramate with other pharmacotherapies for alcohol use disorder (AUD), such as naltrexone. Moreover, the literature is mixed on the effects of two polymorphisms-rs2832407 (in ) and rs1799971 (in )-on response to topiramate and naltrexone, respectively. The authors sought to examine the comparative effectiveness of topiramate and naltrexone in improving outcomes in AUD and to examine the role of the rs2832407 and rs1799971 polymorphisms, respectively, on response to these medications.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!